Document Classification

Section Type: RESULTS

Text: At 2 years, patients taking abatacept had maintained their responses on the American College of Rheumatology (ACR) improvement criteria and the Disease Activity Score in 28 joints (DAS28 ; using the C-reactive protein [CRP] level), as well as their physical function (according to the Health Assessment Questionnaire [HAQ] disability index [DI]) and health-related quality of life (HRQOL ; assessed with the Short Form 36 [SF-36] health survey), that were observed at the end of the double-blind period (year 1 versus year 2 values were 81. 9 % versus 80. 3 % for ACR 20 % improvement, 25. 4 % versus 30. 9 % for a DAS28 [CRP] of < 2. 6, 71. 8 % versus 66. 8 % for the HAQ DI, and 9. 7 versus 10. 6 and 7. 3 versus 7. 2, respectively, for the mean change in the physical and mental components summary scores of the SF-36).